$BLUE
bluebird bio, Inc.

2017 Q4 Form 10-K Financial Statement

#000156459018002704 Filed on February 21, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017 Q2
Revenue $4.168M $7.711M $16.72M
YoY Change 168.56% 396.84% 977.06%
Cost Of Revenue $0.00 $1.100M $420.0K
YoY Change
Gross Profit $4.200M $6.611M $16.30M
YoY Change
Gross Profit Margin 100.77% 85.73% 97.49%
Selling, General & Admin $29.10M $23.00M $21.20M
YoY Change 79.63% 57.53% 15.22%
% of Gross Profit 692.86% 347.91% 130.09%
Research & Development $92.60M $61.55M $64.31M
YoY Change 62.17% -3.84% 54.0%
% of Gross Profit 2204.76% 930.95% 394.64%
Depreciation & Amortization $3.640M $3.620M $3.440M
YoY Change 44.44% 52.1% 39.27%
% of Gross Profit 86.67% 54.76% 21.11%
Operating Expenses $120.9M $85.37M $84.54M
YoY Change 63.68% 7.12% 37.4%
Operating Profit -$116.8M -$77.66M -$67.82M
YoY Change 61.43% -0.62% 13.08%
Interest Expense $500.0K -$1.155M -$2.242M
YoY Change -183.33% 5.0% -328.54%
% of Operating Profit
Other Income/Expense, Net -$100.0K $8.000K -$834.0K
YoY Change -111.11% -99.11% 997.37%
Pretax Income -$117.0M -$78.81M -$70.90M
YoY Change 63.87% 2.08% 20.02%
Income Tax $106.2M $0.00 $0.00
% Of Pretax Income
Net Earnings -$117.2M -$78.81M -$70.90M
YoY Change 64.27% 2.31% 20.48%
Net Earnings / Revenue -2812.57% -1021.98% -424.13%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.515M -$1.728M -$1.729M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.290B $728.8M $1.095B
YoY Change 83.15% 21.26% 90.24%
Cash & Equivalents $758.5M $251.7M $686.3M
Short-Term Investments $531.6M $490.8M $409.1M
Other Short-Term Assets $29.60M $27.20M $18.80M
YoY Change 859.48% 244.3% 164.79%
Inventory
Prepaid Expenses $21.17M $15.04M
Receivables $4.635M
Other Receivables
Total Short-Term Assets $1.323B $758.7M $1.119B
YoY Change 82.65% 24.62% 91.91%
LONG-TERM ASSETS
Property, Plant & Equipment $199.6M $182.4M $180.4M
YoY Change 27.17% 38.46% 65.07%
Goodwill $13.13M $13.13M
YoY Change 0.0%
Intangibles $16.93M $18.81M
YoY Change -18.18%
Long-Term Investments $324.2M $413.9M $101.6M
YoY Change 79.61% 226.68% -50.0%
Other Assets $23.94M $19.80M $24.50M
YoY Change 5.56% 21.87% 131.13%
Total Long-Term Assets $577.8M $647.1M $338.5M
YoY Change 46.68% 109.1% -5.65%
TOTAL ASSETS
Total Short-Term Assets $1.323B $758.7M $1.119B
Total Long-Term Assets $577.8M $647.1M $338.5M
Total Assets $1.901B $1.406B $1.457B
YoY Change 69.98% 53.09% 54.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.87M $12.30M $14.42M
YoY Change -5.79% 83.31% 501.0%
Accrued Expenses $55.20M $41.30M $42.00M
YoY Change 11.52% -17.56% 56.13%
Deferred Revenue $25.67M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.100M $800.0K
YoY Change
Total Short-Term Liabilities $95.61M $76.80M $77.84M
YoY Change 28.28% 13.62% 92.67%
LONG-TERM LIABILITIES
Long-Term Debt $154.7M $154.2M $154.0M
YoY Change 28.81% 54.2% 77.83%
Other Long-Term Liabilities $2.780M $33.40M $90.00K
YoY Change 2216.67% -40.57% -99.84%
Total Long-Term Liabilities $2.780M $187.6M $90.00K
YoY Change 2216.67% 20.1% -99.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $95.61M $76.80M $77.84M
Total Long-Term Liabilities $2.780M $187.6M $90.00K
Total Liabilities $277.1M $264.4M $257.1M
YoY Change 11.44% 18.19% 40.96%
SHAREHOLDERS EQUITY
Retained Earnings -$913.8M -$717.8M
YoY Change 58.19%
Common Stock $494.0K $455.0K
YoY Change 21.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.623B $1.141B $1.200B
YoY Change
Total Liabilities & Shareholders Equity $1.901B $1.406B $1.457B
YoY Change 69.98% 53.09% 54.73%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income -$117.2M -$78.81M -$70.90M
YoY Change 64.27% 2.31% 20.48%
Depreciation, Depletion And Amortization $3.640M $3.620M $3.440M
YoY Change 44.44% 52.1% 39.27%
Cash From Operating Activities -$95.38M -$56.33M -$53.54M
YoY Change 38.01% 42.82% 20.78%
INVESTING ACTIVITIES
Capital Expenditures -$18.83M -$3.900M -$13.49M
YoY Change 44.62% -56.42% 521.66%
Acquisitions
YoY Change
Other Investing Activities $46.42M -$394.9M $72.50M
YoY Change -138.84% -676.64% -6.87%
Cash From Investing Activities $27.59M -$398.8M $59.01M
YoY Change -120.81% -769.77% -22.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 588.3M 6.120M 464.9M
YoY Change 145.37% 151.85% -35584.73%
NET CHANGE
Cash From Operating Activities -95.38M -56.33M -53.54M
Cash From Investing Activities 27.59M -398.8M 59.01M
Cash From Financing Activities 588.3M 6.120M 464.9M
Net Change In Cash 520.5M -449.0M 470.3M
YoY Change 1266.25% -2092.85% 1465.65%
FREE CASH FLOW
Cash From Operating Activities -$95.38M -$56.33M -$53.54M
Capital Expenditures -$18.83M -$3.900M -$13.49M
Free Cash Flow -$76.55M -$52.43M -$40.05M
YoY Change 36.48% 71.96% -5.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
3277000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
74533000
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
2231000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
95612000
CY2017Q4 blue Tenant Improvement Costs Reimbursable Current
TenantImprovementCostsReimbursableCurrent
3112000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
21171000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
1322769000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
199606000
CY2016 blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesArisingDuringPeriodNetOfTax
1142000
CY2015 blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesArisingDuringPeriodNetOfTax
-2220000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3056000
CY2016Q4 blue Tenant Improvement Costs Reimbursable Current
TenantImprovementCostsReimbursableCurrent
8542000
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8209000
CY2017Q4 blue Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
8377000
CY2016Q4 blue Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
3085000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
724214000
CY2017Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
324193000
CY2016Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
180452000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
156955000
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
16931000
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
20694000
CY2017Q4 us-gaap Goodwill
Goodwill
13128000
CY2016Q4 us-gaap Goodwill
Goodwill
13128000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23940000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
22679000
CY2017Q4 us-gaap Assets
Assets
1900567000
CY2016Q4 us-gaap Assets
Assets
1118122000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12873000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13664000
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
54660000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25674000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6209000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2720000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
10408000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
21763000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
40204000
CY2016Q4 blue Financing Lease Obligation Noncurrent
FinancingLeaseObligationNoncurrent
120140000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015 us-gaap Contracts Revenue
ContractsRevenue
14079000
CY2017 blue License And Royalty Revenue
LicenseAndRoyaltyRevenue
13220000
CY2015 us-gaap Revenues
Revenues
14079000
CY2017 blue Cost Of License And Royalty Revenue
CostOfLicenseAndRoyaltyRevenue
1527000
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2001000
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3782000
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1591000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1267000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-71000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
723000
CY2017 blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesArisingDuringPeriodNetOfTax
-3056000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
57065000
CY2017Q4 blue Financing Lease Obligation Noncurrent
FinancingLeaseObligationNoncurrent
154749000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Liabilities
Liabilities
277135000
CY2016Q4 us-gaap Liabilities
Liabilities
248682000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
494000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
407000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1447856000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1149000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-577674000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
869440000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
60000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
120000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1118122000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2540951000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4205000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-913808000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40691000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
1623432000
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40691000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1900567000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49406011
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49406011
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000
CY2017 us-gaap Operating Expenses
OperatingExpenses
367592000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-612000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-264119000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-166723000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-166783000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6145000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
677000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
39756000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
41120000
CY2015 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
-2220000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
850496000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
234731000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1142000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2220000
CY2017 blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
0
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
492000
CY2016 blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
600000
CY2015 blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
0
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
491257000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
477247000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9383000
CY2016 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
1142000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1006570000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31686000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1153000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
53282000
CY2017 blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustments During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentsDuringPeriodNetOfTax
-3056000
CY2015 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
22753000
CY2016 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
15269000
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
53487000
CY2017 blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
-2189000
CY2016 blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
2675000
CY2015 blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
2344000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
13538000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9648000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7419000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
53282000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
39756000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
41120000
CY2016 us-gaap Other Noncash Expense
OtherNoncashExpense
2825000
CY2015 us-gaap Other Noncash Expense
OtherNoncashExpense
1513000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
14318000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6847000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6658000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2541000
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
20889000
CY2015 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
9423000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4565000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
11171000
CY2016 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
1162000
CY2015 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-330000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-189647000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-98429000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
4379000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
8816000
CY2017 blue Payments To Acquire Property Plant And Equipment Including Assets Under Financing Lease Obligations
PaymentsToAcquirePropertyPlantAndEquipmentIncludingAssetsUnderFinancingLeaseObligations
62242000
CY2016 blue Payments To Acquire Property Plant And Equipment Including Assets Under Financing Lease Obligations
PaymentsToAcquirePropertyPlantAndEquipmentIncludingAssetsUnderFinancingLeaseObligations
28029000
CY2015 blue Payments To Acquire Property Plant And Equipment Including Assets Under Financing Lease Obligations
PaymentsToAcquirePropertyPlantAndEquipmentIncludingAssetsUnderFinancingLeaseObligations
7055000
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
755175000
CY2015 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
199179000
CY2017 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1074000
CY2016 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
2025000
CY2015 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
453000
CY2017 blue Proceeds From Reimbursement Of Assets Under Financing Lease Obligation
ProceedsFromReimbursementOfAssetsUnderFinancingLeaseObligation
38021000
CY2016 blue Proceeds From Reimbursement Of Assets Under Financing Lease Obligation
ProceedsFromReimbursementOfAssetsUnderFinancingLeaseObligation
1663000
CY2017 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
574000
CY2017 blue Proceeds From Public Offering Of Common Stock Net Of Issuance Costs
ProceedsFromPublicOfferingOfCommonStockNetOfIssuanceCosts
1006570000
CY2016 blue Proceeds From Public Offering Of Common Stock Net Of Issuance Costs
ProceedsFromPublicOfferingOfCommonStockNetOfIssuanceCosts
234962000
CY2015 blue Proceeds From Public Offering Of Common Stock Net Of Issuance Costs
ProceedsFromPublicOfferingOfCommonStockNetOfIssuanceCosts
477064000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33231000
CY2017 us-gaap Other Noncash Expense
OtherNoncashExpense
3153000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
20092000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
526000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5406000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1024000
CY2017 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
442000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-280553000
CY2017 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-627000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
686204000
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
348225000
CY2017 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
431816000
CY2016 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
443364000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-316003000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
62731000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-571867000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
53282000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39756000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
41120000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2566000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
241534000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
486720000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
479618000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
114618000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-183576000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6934000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10109000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1076174000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164269000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
347845000
CY2017 us-gaap Interest Paid
InterestPaid
11411000
CY2017 blue Assets Acquired Under Financing Lease Obligation
AssetsAcquiredUnderFinancingLeaseObligation
3271000
CY2016 blue Assets Acquired Under Financing Lease Obligation
AssetsAcquiredUnderFinancingLeaseObligation
48034000
CY2015 blue Assets Acquired Under Financing Lease Obligation
AssetsAcquiredUnderFinancingLeaseObligation
61901000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6363000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2089000
CY2017 blue Tenant Improvements Under Financing Lease Included In Tenant Improvements Receivable
TenantImprovementsUnderFinancingLeaseIncludedInTenantImprovementsReceivable
3112000
CY2016 blue Tenant Improvements Under Financing Lease Included In Tenant Improvements Receivable
TenantImprovementsUnderFinancingLeaseIncludedInTenantImprovementsReceivable
8542000
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:2.27%;">bluebird bio, Inc. (the &#8220;Company&#8221; or &#8220;bluebird&#8221;) was incorporated in Delaware on April&#160;16, 1992, and is headquartered in Cambridge, Massachusetts. The Company researches, develops, manufactures and plans to commercialize gene therapies for severe genetic diseases and cancer. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June&#160;30, 2014, the Company acquired all of the outstanding capital stock of Precision Genome Engineering, Inc. (&#8220;Pregenen&#8221;) and in connection therewith, obtained the rights to Pregenen&#8217;s gene editing and cell signaling technology. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2017, the Company had cash, cash equivalents and marketable securities of $1.6 billion. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund current operations for at least the next twelve months. </p></div>
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:2.27%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: fair value estimates used to assess potential impairment of long-lived assets, including goodwill and intangible assets, financing lease obligations, contingent consideration, stock-based compensation expense, accrued expenses, revenue and income taxes.</p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of credit risk and off-balance sheet risk </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:2.27%;">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#8217;s available-for-sale investments primarily consist of U.S. Treasury securities, U.S. government agency securities and certificates of deposit, and potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure. </p></div>
CY2017Q2 us-gaap Revenues
Revenues
16716000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
76745000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
84538000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-69913000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-67822000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-68712000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-70898000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.68
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.73
CY2017 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1992-04-16
CY2017Q4 us-gaap Investments And Cash
InvestmentsAndCash
1600000000
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
9500000
CY2016 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3800000
CY2015 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1600000
CY2017 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
11400000
CY2017Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2016Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
859375000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
606481000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
40000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3579000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
578000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
855797000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
605943000
CY2017 us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
90 days or less
CY2017 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2016 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
704100000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
376100000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
134400000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
95500000
CY2017Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2016Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4479000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
215455000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
169399000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15849000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12444000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9800000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5900000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3700000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19657000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11296000
CY2017Q4 blue Accrued Goods And Services
AccruedGoodsAndServices
29533000
CY2016Q4 blue Accrued Goods And Services
AccruedGoodsAndServices
34275000
CY2017Q4 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
4584000
CY2016Q4 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
2464000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1402000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1492000
CY2017Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1051000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
838000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
654000
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P9Y
CY2013Q2 blue Area Of Leased Space
AreaOfLeasedSpace
43600
CY2013Q2 blue Lease Amendment Effective Month And Year
LeaseAmendmentEffectiveMonthAndYear
2014-06
CY2013Q2 blue Additional Lease Space Agreement
AdditionalLeaseSpaceAgreement
9900
CY2013Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
200000
CY2013Q2 blue Operating Leases Term Of Expiration
OperatingLeasesTermOfExpiration
2017-04
CY2014Q4 us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
300000
CY2013Q2 blue Landlord Contribution For Leasehold Improvements
LandlordContributionForLeaseholdImprovements
7800000
CY2013Q2 blue Letter Of Credit Related To New Lease Agreement
LetterOfCreditRelatedToNewLeaseAgreement
1300000
CY2016Q4 blue Letter Of Credit Related To New Lease Agreement
LetterOfCreditRelatedToNewLeaseAgreement
600000
CY2013Q2 blue Lease Starting Date
LeaseStartingDate
2013-06-03
CY2017 blue Letter Of Credit Related To New Lease Agreement
LetterOfCreditRelatedToNewLeaseAgreement
600000
CY2017 blue Lease Termination Date
LeaseTerminationDate
2017-04-12
CY2016Q4 blue Contractual Obligation Agreement Period
ContractualObligationAgreementPeriod
P5Y
CY2016Q4 blue Contractual Obligation Agreement Renewal Period
ContractualObligationAgreementRenewalPeriod
P3Y
CY2016Q4 blue Contractual Obligation Fees
ContractualObligationFees
3000000
CY2016Q4 blue Contractual Obligation Advance Fees Payment
ContractualObligationAdvanceFeesPayment
2000000
CY2016Q4 blue Contractual Obligation Fees Payable
ContractualObligationFeesPayable
1000000
CY2016Q4 us-gaap Maintenance Costs
MaintenanceCosts
9800000
CY2017 blue Contractual Obligation Termination Description
ContractualObligationTerminationDescription
The Company may terminate this agreement with six months’ notice and a one-time termination fee prior to July 1, 2018, or twelve months’ notice and a one-time termination fee thereafter.
CY2017Q4 blue Future Minimum Commitments Due Current
FutureMinimumCommitmentsDueCurrent
32588000
CY2017Q4 blue Future Minimum Commitments Due In Two Years
FutureMinimumCommitmentsDueInTwoYears
30465000
CY2017Q4 blue Future Minimum Commitments Due In Three Years
FutureMinimumCommitmentsDueInThreeYears
30827000
CY2017Q4 blue Future Minimum Commitments Due In Four Years
FutureMinimumCommitmentsDueInFourYears
31193000
CY2017Q4 blue Future Minimum Commitments Due In Five Years
FutureMinimumCommitmentsDueInFiveYears
25352000
CY2017Q4 blue Future Minimum Commitments Due Thereafter
FutureMinimumCommitmentsDueThereafter
116513000
CY2017Q4 blue Future Minimum Commitments Due
FutureMinimumCommitmentsDue
266938000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
9000000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
8300000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
5700000
CY2017 blue Estimated Future Payments For Contract Terminations Next Fiscal Year
EstimatedFuturePaymentsForContractTerminationsNextFiscalYear
12000000
CY2017 blue Estimated Future Payments For Contract Terminations Year Two
EstimatedFuturePaymentsForContractTerminationsYearTwo
12000000
CY2017 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Common stock are entitled to one vote per share
CY2015Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2941176
CY2016Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3289473
CY2017Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4381500
CY2017Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3243244
CY2015Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
477200000
CY2016Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
234700000
CY2017Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
436800000
CY2017Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
569800000
CY2015Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
170.00
CY2016Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
76.00
CY2017Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
105.00
CY2017Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
185.00
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5970000
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5433000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
1600000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1600000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.781
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.743
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.726
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.015
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3735000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1206000
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
982000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
204000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3755000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1834000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3755000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.17
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
90.95
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
32.39
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
86.84
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
67.91
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
50.60
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
67.91
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
414169000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
234190000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
414169000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
62.03
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
34.22
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
74.65
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
91000000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
15300000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
147900000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-266236000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-210188000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-162287000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-69197000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-53931000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4436000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
115000
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
95000
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
60000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-588000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-24000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.043
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.033
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.042
CY2017 blue Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.027
CY2016 blue Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.053
CY2015 blue Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.064
CY2017 blue Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.128
CY2016 blue Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.150
CY2015 blue Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.146
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.069
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.070
CY2015 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.010
CY2017 blue Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
-0.316
CY2016 blue Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
0.000
CY2015 blue Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.008
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.005
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.146
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.399
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.449
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
194160000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
106064000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
131289000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
87117000
CY2017Q4 blue Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
241000
CY2016Q4 blue Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
631000
CY2017Q4 blue Deferred Tax Assets Capital Lease
DeferredTaxAssetsCapitalLease
42025000
CY2016Q4 blue Deferred Tax Assets Capital Lease
DeferredTaxAssetsCapitalLease
47191000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
12795000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
18231000
CY2017Q4 blue Deferred Tax Assets Capitalized License Fees
DeferredTaxAssetsCapitalizedLicenseFees
13388000
CY2016Q4 blue Deferred Tax Assets Capitalized License Fees
DeferredTaxAssetsCapitalizedLicenseFees
11752000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
25781000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
32172000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
419679000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
303158000
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
4567000
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
8129000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
42062000
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
48902000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
373050000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
246127000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
126900000
CY2017 blue Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxBenefit
106000000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4241000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4009000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3683000
CY2017Q1 us-gaap Revenues
Revenues
6832000
CY2017Q3 us-gaap Revenues
Revenues
7711000
CY2017Q4 us-gaap Revenues
Revenues
4168000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
85369000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
120940000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-77658000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-116772000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-78805000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-117228000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.73
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.52
CY2016Q1 us-gaap Revenues
Revenues
1499000
CY2016Q2 us-gaap Revenues
Revenues
1552000
CY2016Q3 us-gaap Revenues
Revenues
1552000
CY2016Q4 us-gaap Revenues
Revenues
1552000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
58879000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
61527000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
79692000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
73887000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-57380000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-59975000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-78140000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-72335000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-56274000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-58844000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-77025000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-71364000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.52
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.59
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.07
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.88

Files In Submission

Name View Source Status
0001564590-18-002704-index-headers.html Edgar Link pending
0001564590-18-002704-index.html Edgar Link pending
0001564590-18-002704.txt Edgar Link pending
0001564590-18-002704-xbrl.zip Edgar Link pending
blue-10k_20171231.htm Edgar Link pending
blue-20171231.xml Edgar Link completed
blue-20171231.xsd Edgar Link pending
blue-20171231_cal.xml Edgar Link unprocessable
blue-20171231_def.xml Edgar Link unprocessable
blue-20171231_lab.xml Edgar Link unprocessable
blue-20171231_pre.xml Edgar Link unprocessable
blue-ex1038_325.htm Edgar Link pending
blue-ex1039_326.htm Edgar Link pending
blue-ex211_324.htm Edgar Link pending
blue-ex231_9.htm Edgar Link pending
blue-ex311_7.htm Edgar Link pending
blue-ex312_10.htm Edgar Link pending
blue-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201802212145337976654.jpg Edgar Link pending
g201802212145414277711.jpg Edgar Link pending
g201802212145414397712.jpg Edgar Link pending
g201802212145547037713.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending